Thelansis

  Chimeric Antigen Receptor (CAR) T-cell therapy is an advanced immunotherapy used to treat certain types of cancer. It involves genetically modifying a patient's T-cells to express a chimeric antigen receptor on their surface, allowing them to recognize and attack cancer cells expressing specific antigens. The CAR T-cell therapy process includes the following: Collection of T-cells from the patient's blood through leukapheresis. Genetic engineering of T-cells in the lab using a viral vector to introduce the CAR gene. Expansion of genetically modified T-cells to produce a large number of CAR T-cells. Infusion of the CAR T-cells back into the patient's bloodstream. Targeting and destruction of cancer cells by activated CAR T-cells. The market for CAR T-cell therapy has been rapidly growing due to its high success rates in treating blood cancers and its potential in other malignancies. Pharmaceutical and biotech companies have invested significa...